Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $54.93 USD
Change Today +1.76 / 3.31%
Volume 1.6M
ISIS On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $77.80
52 Week Low
08/4/14 - $29.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

isis pharmaceuticals inc (ISIS) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Atlantic Pharmaceuticals Limited. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

390 Employees
Last Reported Date: 03/2/15
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $584.6K
Chief Operating Officer, Director and Member ...
Total Annual Compensation: $1.1M
Senior Vice President of Development
Total Annual Compensation: $636.1K
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Compensation as of Fiscal Year 2014.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Approves Amendment to Bylaws

The board of directors of Isis Pharmaceuticals, Inc. approved the amendment and restatement of the company's bylaws, effective immediately, in order to add a forum selection provision for the adjudication of certain disputes. The new provision, set out in Article XV of the Bylaws, provides that, unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company's stockholders; (iii) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Company's Certificate of Incorporation (as may be amended from time to time) or the Bylaws (as may be amended from time to time); and (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine.

Isis Pharmaceuticals, Inc.(NasdaqGS:ISIS) added to Russell 1000 Index

Isis Pharmaceuticals, Inc. has been added to Russell 1000 Index.

Isis Pharmaceuticals, Inc.(NasdaqGS:ISIS) dropped from Russell 2000 Index

Isis Pharmaceuticals, Inc. will be removed from Russell 2000 Index


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $54.93 USD +1.76

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $48.81 USD +0.99
Acorda Therapeutics Inc $34.36 USD +0.13
Alnylam Pharmaceuticals Inc $127.43 USD +1.97
Depomed Inc $31.50 USD +0.97
Impax Laboratories Inc $48.46 USD +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.3x
Price/Book 23.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at